The Clinical Operations and Regulatory Affairs (CORA) Core will provide the Weill Cornell PEGT the infrastructure and expertise to conduct safe and ethical clinical studies in gene therapy. CORA will ensure that all projects follow the regulations and guidelines of the Food and Drug Administration (FDA), NIH Office of Biotechnology Activities/Recombinant DNA Advisory Committee (OBA/RAC), Institutional Review Board (IRB), and Institutional Biosafety Committee (IBC). The CORA Core consists of four interconnected components: Clinical Operations; Monitoring and Quality Assurances; Regulatory Affairs; and Data Management Analysis. The main purpose of Clinical Operations is to oversee day to day conduct of the clinical study at each site including recruiting patients and scheduling visits and tests, collecting data into case report form, handling all correspondence with local regulatory and monitoring agencies and ensuring the protection of the study individuals. The responsibilities of the Monitoring/QA component are central to the CORA, acting to review Clinical Operations both at Weill Cornell and all local sites, collect relevant information to pass on to the Regulatory Affairs component and to provide completed audited data to the Data Management and Analysis Component. Monitoring/QA oversees the general activities of CORA, including all correspondence with federal regulatory and monitoring agencies and ensure compliance of all sites. The Data Management and Analysis component has the responsibility of collecting data from case report forms provided by the Clinical Operations and audited by the Monitoring/QA, entering and analyzing data in conjunction with statisticians, preparing reports to the Regulatory Affairs component in response to request from the Data Safety Monitoring Board, resolving data discrepancies, and preparing periodic data reports. The CORA Core will also participate in the Education Program of the Weill Cornell PEGT, providing training in Clinical Operations and Regulatory Affairs relating to gene therapy.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
New York
United States
Zip Code
Chiuchiolo, Maria J; Crystal, Ronald G (2016) Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc 13 Suppl 4:S352-69
Nolan, Daniel J; Ginsberg, Michael; Israely, Edo et al. (2013) Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell 26:204-19
Wang, Lan; Rosenberg, Jonathan B; De, Bishnu P et al. (2012) In vivo gene transfer strategies to achieve partial correction of von Willebrand disease. Hum Gene Ther 23:576-88
Krause, Anja; Whu, Wen Zhu; Xu, Yaqin et al. (2011) Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 29:2131-9
Butler, Jason M; Nolan, Daniel J; Vertes, Eva L et al. (2010) Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6:251-64
James, Daylon; Nam, Hyung-song; Seandel, Marco et al. (2010) Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat Biotechnol 28:161-6
Kobayashi, Hideki; Butler, Jason M; O'Donnell, Rebekah et al. (2010) Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 12:1046-56
Shmelkov, Sergey V; Hormigo, Adília; Jing, Deqiang et al. (2010) Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 16:598-602, 1p following 602
Rabbany, Sina Y; James, Daylon; Rafii, Shahin (2010) New dimensions in vascular engineering: opportunities for cancer biology. Tissue Eng Part A 16:2157-9
Wang, G; Qiu, J; Wang, R et al. (2010) Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 17:559-70

Showing the most recent 10 out of 61 publications